In early Parkinson disease, daily subcutaneous lixisenatide reduced motor disability progression at 12 mo.
Where this comes from
- Record sourced from PubMed, PMID 39222514.
- Also identified by DOI 10.7326/ANNALS-24-01662-JC.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Meissner WG, Remy P, Giordana C, et al; LIXIPARK Study Group. <b>Trial of lixisenatide in early Parkinson's disease.</b> N Engl J Med. 2024;390:1176-1185. 38598572.